Down-regulation of lncRNA CASC2 promotes cell proliferation and metastasis of bladder cancer by activation of the Wnt/β-catenin signaling pathway
Metrics: PDF 2715 views | HTML 1317 views | ?
Zhijun Pei1,*, Xian Du2,*, Yafeng Song1, Lin Fan3, Fuyan Li1, Yan Gao1, Ruimin Wu1, Yijia Chen1, Wei Li1, Hong Zhou1, Yi Yang1, Jing Zeng4
1Department of PET Center & Institute of Anesthesiology and Pain, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, 442000, China
2Department of General Surgery II, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, 442000, China
3Department of Ophthalmology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, 442000, China
4Department of Infection Control, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, 442000, China
*These authors have contributed equally to this work
Jing Zeng, email: firstname.lastname@example.org
Keywords: bladder cancer, CASC2, Wnt/β-catenin, proliferation, metastasis
Received: December 27, 2016 Accepted: January 17, 2017 Published: February 09, 2017
Long noncoding RNAs cancer susceptibility candidate 2 (CASC2) have been demonstrated as playing crucial regulatory roles in a few of cancers. However, the biological function of lncRNA CASC2 in bladder cancer are still unclear. In this study, we found that lncRNA CASC2 was significantly down-regulated in bladder cancer tissues and cell lines by quantitative real time-PCR and associated with advanced TNM stage (III/IV). Moreover, overexpression of lncRNA CASC2 remarkably reduced the cell growth, migration and invasion, as well as promoted early apoptosis of bladder cancer cell in vitro. Furthermore, we illustrated that lncRNA CASC2 inhibited Wnt/β-catenin signal pathway activity by decrasing the β-catenin expression and reversing the downstream target gene expression of Wnt signaling pathway. Taken together, lncRNA CASC2 plays an pivotal role in bladder tumorigenesis and progression and may act as a potential biomarker for the treatment of bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.